Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, is indicated as an aid, in the diagnosis of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. Further, it provides the Accelerate Arc system, an instrument and associated one-time-use test kit that automates the clean-up and concentration of microbial cells from positive blood culture samples. Additionally, it offers Accelerate WAVE system, a clinical trial product, performs AST directly from positive blood culture bottles and bacterial isolate colonies to report minimum inhibitory concentrations, based on the principle of digital holographic microscopy, which allows for simultaneous volumetric imaging of a sample suspension at a high spatial resolution, enabling direct observation of phenotypic responses of individual bacterial cells. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.